venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies.
Business Model:
Revenue: $5.7M
Employees: 2-10
Address: 1700 Owens St
City: San Francisco
State: CA
Zip: 94158
Country: US
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams. We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
Contact Phone:
+14158000800
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2015 | Cidara Therapeutics | Series B | 42M |
10/2019 | INBRACE | Series C | 45M |
7/2015 | Outlook Therapeutics | Venture Round | 31M |
10/2021 | HistoWiz | Series A | 32.3M |
5/2015 | Precision BioSciences | Series A | 0 |
11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
3/2017 | ALX Oncology | Convertible Note | 25M |
9/2019 | Pharvaris | Series B | 66M |
12/2013 | Stem Cell Therapeutics | Post-IPO Equity | 0 |
8/2021 | Neurogastrx | Series B | 60M |
4/2014 | Heart Metabolics | Series A | 20M |
1/2021 | FogPharma | Series C | 107M |
6/2018 | Akero Therapeutics | Series A | 65M |
6/2018 | Precision BioSciences | Series B | 0 |
11/2020 | Pharvaris | Series C | 80M |
2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
1/2022 | ImmPACT Bio | Series B | 0 |
1/2018 | Neurogastrx | Series A | 45M |
12/2016 | Impel NeuroPharma | Series C | 36M |
2/2016 | Apellis Pharmaceuticals | Series D | 47M |
9/2020 | Attralus | Series A | 25M |
11/2020 | Elevation Oncology | Series B | 65M |
12/2018 | Akero Therapeutics | Series B | 70M |
2/2020 | ALX Oncology | Series C | 105M |
10/2013 | Seragon Pharmaceuticals | Series A | 30M |
6/2020 | Artiva Biotherapeutics | Series A | 0 |
11/2020 | Stargazer Pharmaceuticals | Series A | 0 |
3/2015 | ALX Oncology | Series A | 36M |
10/2020 | RayzeBio | Series A | 45M |
12/2018 | Impel NeuroPharma | Series D | 67.5M |
12/2020 | Tallac Therapeutics | Series A | 62M |
9/2021 | Attralus | Series B | 116M |
9/2015 | Outlook Therapeutics | Venture Round | - |
1/2022 | Ceptur Therapeutics | Series A | 0 |
3/2012 | Cytos | Post-IPO Equity | 40M |
12/2022 | Entact Bio | Series A | 81M |
6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
9/2014 | Adaptimmune | Series A | 0 |
10/2017 | Harmony Biosciences | Venture Round | 0 |
7/2017 | VYNE Therapeutics | Series C | 50.5M |
8/2015 | Checkmate Pharmaceuticals | Series A | 20M |
1/2020 | NorthSea Therapeutics | Series B | 40M |
12/2012 | Solstice Biologics | Private Equity Round | 7.5M |
1/2013 | Labrys Biologics | Series A | 31M |
4/2019 | Arrakis Therapeutics | Series B | 75M |
8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
9/2021 | Ventyx Biosciences | Series B | 0 |
6/2018 | Metacrine | Series C | 65M |
10/2019 | Aeovian Pharmaceuticals | Series A | 0 |
10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
12/2018 | Checkmate Pharmaceuticals | Series C | 22M |
9/2022 | ACELYRIN | Series C | 0 |
3/2021 | Ventyx Biosciences | Series A | 0 |
8/2015 | Metacrine | Series A | 36M |
11/2021 | ACELYRIN | Series B | 0 |
2/2021 | Artiva Biotherapeutics | Series B | 120M |
12/2020 | RayzeBio | Series B | 105M |
12/2021 | NorthSea Therapeutics | Series C | 0 |
6/2021 | RayzeBio | Series C | 108M |
12/2017 | Metacrine | Series B | 22M |
6/2020 | NFlection Therapeutics | Series A | 20M |
8/2017 | Apellis Pharmaceuticals | Series E | 0 |
6/2017 | Checkmate Pharmaceuticals | Series B | 27M |
10/2018 | Turning Point Therapeutics | Equity | 80M |
10/2021 | CinCor Pharma | Series B | 0 |
11/2022 | FogPharma | Series D | 0 |
9/2021 | INBRACE | Series D | 0 |
1/2013 | Solstice Biologics | Series A | 18M |
1/2022 | ImmPACT Bio | Series B | 0 |
1/2022 | Ceptur Therapeutics | Series A | 0 |
12/2021 | NorthSea Therapeutics | Series C | 0 |
11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
11/2021 | ACELYRIN | Series B | 0 |
10/2021 | HistoWiz | Series A | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
9/2021 | Ventyx Biosciences | Series B | 0 |
9/2021 | INBRACE | Series D | 0 |
9/2021 | Attralus | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|